Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Shana Tova 5781 #Science #Business
    about 1 day ago
  • When even PhRMA doesn't want to be a Trump campaign prop ... A Deal on Drug Prices Undone by White House Insistence…
    about 2 days ago
  • A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $…
    about 2 days ago
  • New post on Science and Enterprise: Mental Health Drug Company Raises $127.5M in IPO #Science #Business
    about 2 days ago
  • A test for SARS-CoV-2 viruses is shown in field tests to return diagnostic results in 90 minutes with accuracy comp…
    about 2 days ago

Please share Science & Enterprise

Biogen Idec, Samsung to Form $300M Biosimilar Venture

Beakers (


Biogen Idec, a biotechnology company in Weston, Massachusetts, and the Korean conglomerate Samsung will form a joint venture to develop and market follow-on biologic drugs known as biosimilars. Investments by both companies in the venture will total $300 million.

Samsung will contribute $255 million of the $300 million for an 85 percent stake in the joint venture, and Biogen Idec will contribute $45 million for a 15 percent stake. The joint venture, based in Korea, will contract with Biogen Idec and Samsung Biologics for technical development and manufacturing services.

Samsung formed Samsung Biologics in April 2011 to specialize in biopharmaceutical manufacturing. “By combining Biogen Idec’s expertise in biologics with our business acumen and proven record of success in new business development, we are taking a significant step toward becoming a major player in the biopharmaceutical industry,” says Tae-Han Kim, the CEO of Samsung Biologics.

Biosimilars are generic versions of biologics therapies, developed after the expiration of patents on the original versions. The joint venture does not plan to develop biosimilars of Biogen Idec’s own products. The company has specialized in therapeutics for neurodegenerative diseases, hemophilia, and autoimmune disorders.

Read more:

*     *     *

1 comment to Biogen Idec, Samsung to Form $300M Biosimilar Venture